A 546-patient, multicountry phase 3 trial randomized participants on insulin glargine (± metformin/SGLT2 inhibitors) to orforglipron 3, 12, or 36 mg daily versus placebo for 40 weeks. Superiority ...
Anne Komé, PharmD, CPP, BCACP, CDCES, a clinical pharmacist practitioner in the Endocrinology Clinic at the UNC Chapel Hill ...
Inhaled insulin (Afrezza; MannKind Corporation) continues to build a case for broader adoption in pediatric diabetes care.
Diabetes disparities drive unequal CGM access and amputation risk, highlighting the need to address social, provider, and ...
The Medicare GLP-1 Bridge's July 1 launch is now the only concrete milestone on the calendar. Whether it becomes the ...
The moisturizer, sunscreen, or shampoo used in daily routines may contain dozens of plastic-associated chemicals linked to ...
Ajai Chari, MD, unpacks resistance mechanisms, treatment sequencing, and why myeloma’s future may be brighter than anyone ...
After FDA approval for children 6 and older, ADA data show inhaled insulin's safety and satisfaction benefits, but clinician ...
SEER-Medicare data (n=54,344; mean age 77.7 years) showed significant unadjusted Black-White gaps in localized diagnosis, ...
Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave ...
The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention ...
New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results